Lung Therapeutics Employee Directory
Biotechnology ResearchTexas, United States2-10 Employees
Lung Therapeutics is a small biotechnology research company based in Austin, Texas. In October 2023 it was acquired by Aileron Therapeutics, which subsequently rebranded as Rein Therapeutics. Rein now positions itself as a pharmaceutical company focused on niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Its lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis and LTI-01 for loculated pleural effusion, within a proprietary pipeline aimed at improving outcomes relative to existing treatments. Additionally, Rein entered an exclusive option agreement in October 2024 with Advancium Health Network regarding ALRN-6924, a clinical-stage oncology asset previously developed under Aileron.